Correspondence 0001104659-24-011778 from Bio Green Med Solution, Inc. (BGMS)
Bio Green Med Solution, Inc.
Date: Feb. 7, 2024 · CIK: 0001130166 · Accession: 0001104659-24-011778
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276623
Referenced dates: January 26, 2024
Letter
919 Third Avenue
New York, NY 10022
212 935 3000
mintz.com
February 7, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E. Washington, D.C. 20549
Attention: Jessica Dickerson and Laura Crotty, Office of Life Sciences
Re: Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed January 19, 2024
File No. 333-276623 (the “Registration Statement”)
Ladies and Gentlemen:
We are submitting this letter on behalf of Cyclacel Pharmaceuticals, Inc. (the “Company”) in response to the comment from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) received by letter dated January 26, 2024 (the “Comment Letter”) from the Division of Corporation Finance, Office of Life Sciences, to Spiro Rombotis, President & Chief Executive Officer of the Company, relating to the above-referenced Registration Statement. In conjunction with this letter, the Company is filing Amendment No. 1 to its Registration Statement on Form S-1 (the “Amended Registration Statement”) with the Commission.
For reference, we have set forth below in italics the Staff’s comment from the Comment Letter and have keyed the Company’s response to the numbering of the comment and the headings used in the Comment Letter. The response is based on information provided to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. by representatives of the Company. Page numbers referred to in the response reference the applicable pages of the Amended Registration Statement.
Form S-1 filed January 19, 2024
Incorporation of Certain Documents by Reference, page 31
Comment 1: It appears that you are not eligible to incorporate by reference into your Form S-1, given that you have not filed your annual report for your most recently completed fiscal year. Please revise your registration statement to provide all disclosure required by Form S-1 or otherwise advise. See General Instruction VII.C to Form S-1..
Response 1: The Staff’s comment is acknowledged, and the Company has provided all disclosure required by Form S-1 in the Amended Registration Statement to address the Staff’s comment.
* * * * *
Boston Los Angeles New York San Diego San Francisco TORONTO Washington
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.
MINTZ
February 7, 2024
Page 2
We hope that the above response will be acceptable to the Staff. Please do not hesitate to call me at (212) 692-6732 with any comments or questions regarding the proposed disclosure. We thank you for your time and attention.
Sincerely,
/s/ Jeffrey Schultz
Show Raw Text
CORRESP
1
filename1.htm
919 Third Avenue
New York, NY 10022
212 935 3000
mintz.com
February 7, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E. Washington, D.C. 20549
Attention: Jessica Dickerson and Laura Crotty, Office of Life Sciences
Re: Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed January 19, 2024
File No. 333-276623 (the “Registration Statement”)
Ladies and Gentlemen:
We are submitting this letter on behalf of Cyclacel Pharmaceuticals,
Inc. (the “Company”) in response to the comment from the staff (the “Staff”) of the U.S. Securities
and Exchange Commission (the “Commission”) received by letter dated January 26, 2024 (the “Comment Letter”)
from the Division of Corporation Finance, Office of Life Sciences, to Spiro Rombotis, President & Chief Executive Officer of the Company,
relating to the above-referenced Registration Statement. In conjunction with this letter, the Company is filing Amendment No. 1 to its
Registration Statement on Form S-1 (the “Amended Registration Statement”) with the Commission.
For reference, we have set forth below in italics the Staff’s
comment from the Comment Letter and have keyed the Company’s response to the numbering of the comment and the headings used in the
Comment Letter. The response is based on information provided to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. by representatives
of the Company. Page numbers referred to in the response reference the applicable pages of the Amended Registration Statement.
Form S-1 filed January 19, 2024
Incorporation of Certain Documents by Reference, page 31
Comment 1: It appears that you are not eligible to incorporate
by reference into your Form S-1, given that you have not filed your annual report for your most recently completed fiscal year. Please
revise your registration statement to provide all disclosure required by Form S-1 or otherwise advise. See General Instruction VII.C to
Form S-1..
Response 1: The Staff’s comment is
acknowledged, and the Company has provided all disclosure required by Form S-1 in the Amended Registration Statement to address the Staff’s
comment.
* * * * *
Boston Los Angeles New York San Diego San Francisco TORONTO Washington
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY
AND POPEO, P.C.
MINTZ
February 7, 2024
Page 2
We hope that the above response will be acceptable
to the Staff. Please do not hesitate to call me at (212) 692-6732 with any comments or questions regarding the proposed disclosure. We
thank you for your time and attention.
Sincerely,
/s/ Jeffrey Schultz
Jeffrey Schultz
cc: Securities and Exchange Commission
Jessica Dickerson
Laura Crotty
Cyclacel Pharmaceuticals, Inc.
Spiro Rombotis
Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.
Joel Papernik